Intervention Review

You have full text access to this OnlineOpen article

Interventions for the prevention of mycobacterium avium complex in adults and children with HIV

  1. Muhammed Mubashir B Uthman1,2,*,
  2. Olalekan A Uthman3,
  3. Ismail Yahaya4,5

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 30 APR 2013

Assessed as up-to-date: 11 JAN 2013

DOI: 10.1002/14651858.CD007191.pub2

How to Cite

Uthman MMB, Uthman OA, Yahaya I. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD007191. DOI: 10.1002/14651858.CD007191.pub2.

Author Information

  1. 1

    University of Ilorin, Department of Epidemiology & Community Health, Faculty of Clinical Sciences, College of Health Sciences, Ilorin, Kwara, Nigeria

  2. 2

    University of Ilorin Teaching Hospital (UITH), Ilorin, Nigeria

  3. 3

    Division of Health Sciences, Warwick Medical School, The University of Warwick, Warwick-Centre for Applied Health Research and Delivery (WCAHRD), Warwick, UK

  4. 4

    Mid-Sweden University, Department of Public Health, Sundsvall, Sweden

  5. 5

    Heart of England NHS Foundation Trust, Birmingham, UK

*Muhammed Mubashir B Uthman, uthmanmb@yahoo.com. mubashiruthman@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Abrams 1993 {published data only}
  • Abrams DI, Mitchell TF, Child CC, Shiboski SC, Brosgart CL, Mass MM. Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. J Infect.Dis. 1993;167(0022-1899 (Print), 0022-1899 (Linking), 6):1459-63.
Benson 2000 {published data only}
  • Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases 2000;181(4):1289-97.
Currier 2000 {published data only}
  • Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2000;133:493-503.
El-Sadr 2000 {published data only}
  • El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. New England Journal of Medicine 2000;342:1085-92.
Havlir 1996 {published data only}
  • Havlir DV, Dub‚ MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. The New England journal of medicine 1996;335:392-8.
Nightingale 1993 {published data only}
  • Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. The New England journal of medicine 1993;329:828-33.
Oldfield 1998 {published data only}
  • Oldfield EC, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998; Vol. 26, issue 3:611-9. [: CN-00681233]
Pierce 1996 {published data only}
  • Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. The New England journal of medicine 1996;335:384-91.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Chu 2011 {published data only}
  • Chu J, Sloan CE, Freedberg KA, Yazdanpanah Y, Losina E. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. AIDS Res Ther 2011;8(1742-6405 (Electronic), 1742-6405 (Linking)):14.
Cohn 1997 {published data only}
  • Cohn DL. Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. Drugs 1997;54(SUPPL. 2):8-15.
Currier 1997 {published data only}
  • Currier JS, McCutchan JA. Alternative regimens for the prophylaxis of Mycobacterium avium complex in acquired immune deficiency syndrome (AIDS). American Journal of Medicine 1997;102(5 C):28-31.
Dube 1997 {published data only}
  • Dube MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. Journal of Infectious Diseases 1997;176(5):1225-32.
Dube 1999 {published data only}
  • Dube MP, Torriani FJ, See D, Havlir DV, Kemper CA, Leedom JM, et al. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. Clinical Infectious Diseases 1999;28(1):136-8.
Green 2004 {published data only}
McNabb 2000 {published data only}
  • McNabb J, Lacy MK, Ross JW, Rousseau M, Nightingale CH, Nicolau DP. Randomized, crossover adherence trial of azithromycin and clarithromycin for Mycobacterium avium complex prophylaxis in AIDS patients. Infectious Diseases in Clinical Practice 2000;9:27-32.
Moore 1995 {published data only}
Ong 1999 {published data only}
Ostroff 1995 {published data only}
  • Ostroff SM, Spiegel RA, Feinberg J, Benson CA, Horsburgh CR Jr. Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Clin.Infect.Dis. 1995;21 Suppl 1(1058-4838 (Print), 1058-4838 (Linking)):S72-6.
Siegal 1996 {published data only}

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Benson 1993
  • Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clinical infectious diseases 1993;17(1):7-20.
Benson 2004
  • Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, CDC, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 2004; Vol. 53, issue RR-15:1-112.
Chaisson 1994
  • Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Annals of internal medicine 1994;121(12):905-11.
Chaisson 1997
  • Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.. AIDS 1997;11(3):311-7.
Clive 2001
  • Clive AP, Alan S, Karstaedt, Mark H. Prevalence and Clinical Manifestations of Disseminated Mycobacterium avium Complex Infection in South Africans with Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases 2001;33(12):2068-2071.
Dautzenberg 1997
  • Dautzenberg B. Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. Drugs 1997;54:28-9.
Dworkin 2000
  • Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. Journal of Infectious Disease 2000;182:611-615.
Gilks 1995
  • Gilks CF, Brindle RJ, Mwachari C, Batchelor B, Bwayo J, Kimari J, et al. Disseminated Mycobacterium avium infection among HIV-infected patients in Kenya. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1995;8(2):195-8.
Hawkins 1986
  • Hawkins CC, Gold JW, Whimbey E, Kiehn TE, Brannon P, Cammarata R, et al. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Annals of internal medicine 1986;105(2):184-8.
Heifets 1993
  • Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993;37(11):2364-70.
Higgins 2011
  • Higgins, J.P.T, Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Vol. 5.1.0, The Cochrane Collaboration, 2011.
Horsburgh 1991
  • Horsburgh CR Jr, Havlik JA, Ellis DA, Kennedy E, Fann SA, Dubois RE, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. American review of respiratory disease 1991;144(3 pt 1):557-9.
Inderlied 1993
Maartens 2002
MacGregor 2005
  • MacGregor RR, Hafner R, Wu JW, Murphy RL, Perlman DC, Bermudez LE. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS research and human retroviruses 2005;21(8):689-95.
MMWR 1993
  • Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 1993; Vol. 42, issue RR-9:14-20.
Naik 1989
  • Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Journal of antimicrobial chemotherapy 1989;33(9):1614-6.
Nightingale 1992
  • Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. Journal of infectious diseases 1992;165(6):1082-5.
Phillips 1999
  • Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. Journal of acquired immune deficiency syndromes and human retrovirology 1999;20(2):122-8.
Shafran 1998
  • Shafran SD. Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. International journal of infectious diseases 1998;3(1):39-47.
US DHHS 2011
  • US DHHS. Guide for HIV/AIDS Clinical Care. Section 3: Health Care Maintenance and Disease Prevention: opportunistic infection prophylaxis. U.S. Department of Health and Human Services Health Resources and Services Administration HIV/AIDS Bureau, 2011.
WHO 2004
  • WHO. TB/HIV: a clinical manual. http://whqlibdoc.who.int/publications/2004/9241546344.pdf. (accessed on 13/09/07). 2nd 2004.